search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


17 resulaten gevonden voor Multiple myeloma (Kahler's disease) in trials

Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.
- TRIAL ID
NTR5350
- ACRONYMHOVON 129 PCL
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial.
- TRIAL ID
NTR4910
- ACRONYMHOVON 126 MM
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.
- TRIAL ID
NTR4869
- ACRONYMThe Selvedex trial
A randomized phase II study for evaluation of T cell depleted non myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapy.
- TRIAL ID
NTR2958
- ACRONYMHOVON 108 MM
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
- TRIAL ID
NTR2528
- ACRONYMHOVON 95 MM
Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years.
- TRIAL ID
NTR1645
- ACRONYMHOVON 76 MM
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma.
- TRIAL ID
NTR1440
- ACRONYMHOVON 86 MM
RNA-DC vaccination in multiple myeloma.
- TRIAL ID
NTR1086
- ACRONYMN/A
High dose simvastatin combined with standard chemotherapy in patients with refractory Multiple Myeloma: a phase II study.
- TRIAL ID
NTR988
- ACRONYMHigh dose simvastatin combined with standard chemotherapy in patients with refractory Multiple Myeloma: a phase II study
Vertebroplasty versus radiotherapy as palliative treatment of vertebral metastases of multiple myeloma (M. Kahler)
- TRIAL ID
NTR987
- ACRONYMVERAMM
Bortezomib therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation
- TRIAL ID
NTR949
- ACRONYMDLI-Velcade studie
Infusion of host dendritic cells to improve the graft versus myeloma effect of donor lymphocyte infusion. A phase I/II study.
- TRIAL ID
NTR625
- ACRONYMAPC study
Myelo-ablative chemo/radiotherapy and autologous stem cell transplantation as compared to only chemotherapy in patients with multiple myeloma.
- TRIAL ID
NTR321
- ACRONYMHOVON 24 MM
A randomized phase III study on the effect of Thalidomide combined with Adriamycin, Dexamethasone (AD) and High Dose Melphalan in patients with multiple myeloma.
- TRIAL ID
NTR238
- ACRONYMHOVON 50 MM / GMMG-HD3
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.
- TRIAL ID
NTR233
- ACRONYMHOVON 50 MM
Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone.
- TRIAL ID
NTR232
- ACRONYMHOVON 49 MM
A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance in patients with multiple myeloma.
- TRIAL ID
NTR213
- ACRONYMHOVON 65 MM / GMMG-HD4